Phase 2 Clinical Trial Results
Retatrutide produced the largest weight loss ever recorded in a clinical trial — averaging 24.2% of body weight over 48 weeks in Phase 2 at the highest dose. Phase 3 trials are ongoing.
Source: Phase 2 Trial (12 mg dose) | Duration: 48 weeks | Individual results vary.
Important: Results shown are from clinical trials and represent averages. Individual results vary significantly based on dose, diet, exercise, metabolic health, and adherence. This page is for informational purposes only. Consult a qualified healthcare professional before use.
Starting dose: 1 mg/week. Appetite suppression begins early. GI side effects are most prominent during this initial phase. Weight loss is modest (1–3 lbs) as the body adjusts.
Dose increases from 1 mg to 4 mg/week. Average weight loss of 6–8% of body weight by week 12 in Phase 2 data. Appetite suppression becomes pronounced. Energy expenditure increases.
Dose escalation continues (4 mg → 8 mg → 12 mg). The fastest rate of weight loss occurs during this phase. Average cumulative loss of 16–18% of body weight by week 24 at the highest dose.
Maintenance dose of 12 mg/week. Average total loss of 24.2% at week 48 in Phase 2 (12 mg group). This exceeds tirzepatide's 72-week results, achieved in only 48 weeks. Phase 3 data will clarify long-term outcomes.
The 12 mg dose produces significantly more weight loss than lower doses. The dose-response relationship is steep.
Retatrutide's glucagon receptor agonism increases energy expenditure, which may explain its superior efficacy over tirzepatide.
Higher GI side effect rates at the 12 mg dose may limit tolerability for some patients. Slow escalation is critical.
Phase 2 results are promising but Phase 3 trials will provide more definitive long-term efficacy and safety data.
Retatrutide is not yet FDA-approved. These results are from clinical trials only.
Phase 2 clinical trials show an average weight loss of 24.2% of body weight over 48 weeks at the 12 mg dose. This is the largest weight loss ever recorded in a clinical trial for any obesity medication.
Phase 2 data suggests retatrutide produces greater weight loss than tirzepatide (24.2% vs 22.5%), achieved in fewer weeks (48 vs 72). However, retatrutide is not yet FDA-approved and Phase 3 data is needed.
Retatrutide is currently in Phase 3 clinical trials. Potential FDA approval could come in 2026–2027 if trials are successful.
Phase 2 data suggests retatrutide produces more weight loss in less time than semaglutide. The 24.2% loss at 48 weeks exceeds semaglutide's 14.9% at 68 weeks.
Retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors) while tirzepatide is a dual agonist (GLP-1, GIP). The additional glucagon receptor agonism increases energy expenditure, which may explain retatrutide's superior efficacy.
Purgo Labs provides HPLC-verified, third-party tested Retatrutide for legitimate research purposes. Every batch includes a certificate of analysis.
Shop Retatrutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.